↓ Skip to main content

Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout

Overview of attention for article published in Clinical Therapeutics, November 2009
Altmetric Badge

Mentioned by

patent
3 patents

Readers on

mendeley
77 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Febuxostat: A selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout
Published in
Clinical Therapeutics, November 2009
DOI 10.1016/j.clinthera.2009.11.033
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United States 3 4%
Slovenia 1 1%
Norway 1 1%
Unknown 72 94%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Bachelor 14 18%
Researcher 10 13%
Other 9 12%
Student > Postgraduate 9 12%
Student > Ph. D. Student 6 8%
Other 16 21%
Unknown 13 17%
Readers by discipline
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 17 22%
Medicine and Dentistry 17 22%
Chemistry 10 13%
Biochemistry, Genetics and Molecular Biology 6 8%
Agricultural and Biological Sciences 6 8%
Other 6 8%
Unknown 15 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2015.
All research outputs
#8,534,976
of 25,374,647 outputs
Outputs from Clinical Therapeutics
#1,283
of 3,850 outputs
Outputs of similar age
#38,682
of 108,542 outputs
Outputs of similar age from Clinical Therapeutics
#10
of 22 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,850 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 108,542 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.